at Zacks.com (Jan 16, 2015)
The FDA has withdrawn approval of Impax (IPXL -1%) and Teva's (TEVA -0.5%) Budeprion XL 300 mg, saying it's reviewed new data that indicates it's not therapeutically equivalent to Wellbutrin XL 300 mg. Both companies have stopped shipping the product and are issuing detailed information to their customers. The FDA added that its announcement does not affect the Impax/Teva Budeprion 150 mg product or generic Budeprion products made by other manufacturers.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 15, 2015)
at Zacks.com (Jan 13, 2015)
at Zacks.com (Jan 9, 2015)
at Benzinga.com (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs